ABSTRACT

Dipeptidyl peptidase-IV (DPP-IV) inhibitors are widely used drugs of choice for treating Type 2 Diabetes Mellitus (T2DM). These are mostly gliptin molecules. DPP-IV is responsible for the degradation of Glucagon-like polypeptide -I which is responsible for the enhancement of the activity of the insulin. So, the therapeutic strategy is to use these drugs to inhibit DPP-enzyme, hence prohibiting the degradation of GLP-I. A series of DPP-IV inhibitors are used for the effective management of T2DM. Many DPP-IV inhibitors are still in clinical trials. The discovery and the need for developing novel DPP-IV inhibitors is the newer approach. Thesedrugs have shown pharmacological effects in various metabolic disorders like controlling T2DM majorly and showing anti-parkinsonism, Anti-obesity, Anti-neoplastic, cardioprotective action, anti-inflammatory, and analgesic in diabetic neuropathy. The comparative study of pharmacological properties and predictions of 20 gliptins which are widely used as DPP-IV inhibitors helps to repurpose the same in different biological diseased conditions. It will save time and expenditure on the development of the new drug and the study of drug profiles through clinical investigations. The analysis method and prediction studies are beneficial for the prospects of this class of drugs specifically. Keywords: DPP-IV inhibitors, Anti-diabetic agent, Anti-obesity agent, Anti-parkinson agent, activity predictions
Publication date: 01/10/2024

https://ijbpas.com/pdf/2024/October/MS_IJBPAS_2024_9716.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.10.9716